ReviewFrontiers in pediatrics2021
Prophylactic Erythropoietin for Neuroprotection in Very Preterm Infants: A Meta-Analysis Update.
Review in Frontiers in pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Association of anemia and necrotizing enterocolitis in neonates: Systematic review and meta-analysis of transfusion thresholds, erythropoietin trials, and observational studies.Journal of neonatal-perinatal medicine · 2026Pooled it
- Early erythropoiesis-stimulating agents in preterm or low-birthweight infants.The Cochrane database of systematic reviews · 2026Pooled it
- Strategies for addressing the needs of children with or at risk of developmental disabilities in early childhood by 2030: a systematic umbrella review.BMC medicine · 2024Pooled it
- Early erythropoietin for preventing necrotizing enterocolitis in preterm neonates - an updated meta-analysis.European journal of pediatrics · 2022Pooled it
- Effect of Early High-Dose Recombinant Human Erythropoietin on Behavior and Quality of Life in Children Aged 5 Years Born Very Preterm: Secondary Analysis of a Randomized Clinical Trial.JAMA network open · 2022Trial
- Safety and Short-term Outcomes of High-Dose Erythropoietin in Preterm Infants With Intraventricular Hemorrhage: The EpoRepair Randomized Clinical Trial.JAMA network open · 2022Trial
- From Erythropoiesis to Circuit Rewiring: Erythropoietin as a Precision Tool for Neurorestoration.International journal of molecular sciences · 2026Review
- The role of early administration of erythropoiesis-stimulating agents in preterm neonatal neuroprotection: a systematic review and meta-analysis.Journal of perinatology : official journal of the California Perinatal Association · 2026Review
- Neuroprotective effects of caffeine, erythropoietin, magnesium sulfate, and thyroxine in preterm infants: a network meta-analysis.Translational pediatrics · 2025Article
- Personalized Therapeutic Advances in Erythropoietin Signaling: From Anemia Management to Extensive Clinical Applications.Pharmaceutics · 2025Review
- Darbepoetin alpha has an anxiolytic and anti-neuroinflammatory effect in male rats.BMC immunology · 2024Article
- Early High-Dose Erythropoietin and Cognitive Functions of School-Aged Children Born Very Preterm.JAMA network open · 2024Observational
- Neurodevelopmental outcomes of preterm infants.Clinical and experimental pediatrics · 2023Article
- Recent research on the effect of common treatments given in the perinatal period on neurodevelopment in offspring.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Review
- Thresholds for blood transfusion in extremely preterm infants: A review of the latest evidence from two large clinical trials.Frontiers in pediatrics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A meta-analysis update of randomized controlled trials investigating recombinant human erythropoietin suggests improved neurodevelopmental outcome in preterm infants. There was substantial heterogeneity, which could be ascribed to a single trial. Exclusion of this trial featuring a high risk of bias abolished heterogeneity and any effects of recombinant human erythropoietin treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.